Hiroshi Iwamoto

22PUBLICATIONS
44CO-AUTHORS
Exercise physiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jun 12, 2026
Diversity of Factors Associated with Physical Inactivity in Patients with Asthma Based on Activity Intensity.

|Jun 09, 2026
Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.

|Jun 04, 2026
Baseline Neutrophil-To-Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non-Small Cell Lung Cancer: A Two-Cohort Study With Retrospective Discovery and Prospective Validation.

|Nov 06, 2025
Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

Masahiko Sumii, Takeshi Masuda, Kiyofumi Shimoji

|Feb 26, 2025
Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer.

Tetsu Hirakawa, Kakuhiro Yamaguchi, Kunihiko Funaishi

|Feb 20, 2024
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis.

Shinichiro Miura, Hiroshi Iwamoto, Masashi Namba

Pageof 4

Frequent Collaborators

10 joint publications

Takeshi Masuda

9 joint publications

Taku Nakashima

9 joint publications

Kakuhiro Yamaguchi

8 joint publications

Yasushi Horimasu